Forum Topics BOT BOT BOT @ Bell Potter Conference

Pinned straw:

Added 4 weeks ago

Botanix Pharmaceuticals (BOT) | Bell Potter Healthcare Conference 2024

Matthew Callahan, Executive Director at Botanix Pharmaceuticals (BOT) presents at the Bell Potter Healthcare Conference 2024.

https://www.youtube.com/watch?v=Yqp8Fbq_2pg

Aaronfzr
Added 4 weeks ago

Very interesting presentation. I notice he dodged the question about relative efficacy and economics of other products, but we can probably find that without too much trouble. 9/10 patients achieving a 2-step improvement is pretty darn good.

Really interesting to see how well they are planning to use telehealth to accelerate physician access, diagnosis and start of treatment- he isn't exaggerating to say that can save 3 months; probably even more for more remote patients. Concerns re; telehealth viability notwithstanding, for just $100 in platform fees this is money-for-jam, and if it works well will really give them leverage in US and possibly wider.

great talk, thanks for sharing


17

mikebrisy
Added 4 weeks ago

@Arizona ditto.

@Aaronfzr I think I heard Matt say it’s priced comparably to Qbrexa (or did I imagine that), and because they haven’t done a head-to-head comparison, he’d know better than to answer the relative efficacy question. But as you say, a 2-step improvement with c. 90% seeing some benefit is encouraging. If that translates to real world, then this should do well.

From my assessment, the Japanese data indicates better uptake that is assumed by the market for Sofdra in the US, however, I think ECCLOCK is now plateauing in Japan. But I have no idea how good the sales and marketing is in Japan.

This wild card here is the DTC marketing.

One thing I learned today is that the initial script is for 11 refills, if I heard correctly. Can’t believe I missed that before.

2025 is definitely a key year for this one.


21

Aaronfzr
Added 4 weeks ago

Yep, 11 refills is a great setup. Must be a US thing, perhaps backed up by the trials. Here one would only get 5... coupled with direct distribution and auto-refill, very powerful model. Not clear how it works with a co-pay (direct charge each time, up-front charge?)

15

Arizona
Added 4 weeks ago

@Aaronfzr Yes that would be interesting to know, how payment will come through from insurers. Up front or monthly.

Matt seems to indicate that there will be an update re uptake by the Hyper Hydrosis Society members, "in a few weeks time".

Can anyone tell me: The term "commercial lives" is that another way of saying customer/patient?

13

mikebrisy
Added 4 weeks ago

@Arizona yes, commercial lives are paying patients.

In terms of payment, this will depend on the agreement between $BOT and the insurer/payer.

It is quite common in the US for pharmacos to be paid per dispensing event, even though the patient will typically pay any co-payment per refill.

However, it would not seem to me to be commercially savvy for an insurer to reimburse $BOT upfront for an 11-month refill script, when a proportion of patients will abandon the treatment before or just after the first refill!

So, it will come down to what’s in the coverage agreement.

We’ll get a sense of that by tracking revenue and cash over time. I expect $BOT to recognise revenue at the refill level.

In any event, I expect $BOT to report the numbers of patients and the refill rate. Over time, I’d hope they will also report patient persistency, as that is a key long per value driver.

At US$450/patient/month net to $BOT there’s a lot of value in a patient that tries the treatment and stays on it!

15

Arizona
Added 4 weeks ago

Thanks @mikebrisy Monthly payment would make more sense.

The whole process seems very "sticky" in that, as I understand it, the customer is onboarded, they are sent the first months supply and the following 11 months supplies are automated in the system. Then presumably that rolls over into the following year etc etc.

Maybe I'm getting ahead of myself. It will certainly be very interesting to see the numbers who get on board from the HHS and then more broadly.

The fact that it's legal to advertise these products in the US as opposed to Japan must make a difference to the roll out. Then the HHS involvement seems to be a master stroke.

15